



Legislative Updates as of 05/12/2026

Georgia Primary Elections

Primary elections play an important role in shaping leadership at the local, state, and national levels - and they directly affect the policy environment our members operate in.

Early voting for Georgia's May 19 primary is now open through May 15. For members with demanding schedules, early voting offers more flexibility.

Official, nonpartisan information on voter registration, voting options, key deadlines, locations, and hours is available through the Georgia Secretary of State's office: sos.ga.gov and mvp.sos.ga.gov.

This information is shared for awareness purposes only and does not represent an endorsement of any candidate, party, or campaign.

MAY MATTERS FOR LIFE SCIENCES IN GEORGIA

PRIMARY ELECTIONS MATTER MOST. HERE'S WHY.

GEORGIA LIFE SCIENCES

#GAMATTERS
#MAYMATTERS
GAMATTERS.US

The banner features a white background with orange borders. It includes the text "MAY MATTERS FOR LIFE SCIENCES IN GEORGIA" in large, bold letters, an orange outline of the state of Georgia with a checkmark, the Georgia Life Sciences logo, a QR code, and a photograph of two scientists in a lab. The bottom right corner contains the hashtags and website URL.

State Policy Update

Georgia House leadership has appointed members to the 2026 Blue Ribbon Study Committee on Pharmacy Benefits Managers (PBMs) and Consumers' Access to Prescription Medications, signaling continued legislative focus on drug pricing, reimbursement practices, and patient access issues ahead of the next session. Study committees often serve as the foundation for future legislation, and continued scrutiny of PBMs remains a growing issue at both the state and federal levels.

The committee will be chaired by Rep. Ron Stephens (R-Savannah) and includes bipartisan representation from House leadership and key healthcare policymakers. For the full announcement, visit the [Georgia House Press Releases](#).

Federal Policy Watch

Federal policymakers continue balancing healthcare affordability, innovation, public trust, and global competitiveness as Congress prepares to return from recess.

This week's activity highlighted continued scrutiny of federal health agencies, renewed attention on drug pricing policy, and growing concern around biotechnology, national security, and supply chain resilience.

Key developments included:

- Continued debate around Most Favored Nation (MFN) drug pricing proposals and their potential impact on innovation and patient access
- Ongoing congressional focus on healthcare affordability, prior authorization reform, hospital pricing, and the 340B program
- FDA operational and regulatory initiatives aimed at accelerating inspections and modernizing oversight processes
- Emerging congressional concern around the use of clinical trial data generated in China and other foreign adversary nations, reflecting broader discussions on research security and global competitiveness

At the same time, bipartisan conversations continue around physician payment reform, clinical trial modernization, Medicare policy, and domestic manufacturing capacity.

State-level policy activity also remains active nationwide, including legislation related to Prescription Drug Affordability Boards (PDABs), 340B policy, AI oversight, biologic substitution, antitrust policy, and R&D tax incentives.

What to Watch This Week

As Congress returns to session, key issues expected to remain front and center include:

- FDA oversight and leadership developments
- Drug pricing and reimbursement reform
- PBM and 340B scrutiny
- Clinical trial modernization and domestic manufacturing
- Biotechnology competitiveness and China-related policy

Bottom Line

Healthcare affordability, innovation policy, national security, and regulatory modernization are becoming increasingly interconnected in Washington.

For life sciences companies, the pace of policy activity reinforces the importance of continued engagement and proactive monitoring as policymakers shape the next phase of healthcare and innovation policy.

Upcoming Federal Hearings

Congress is expected to resume a more active hearing schedule next week, including anticipated oversight and appropriations discussions involving FDA and broader HHS priorities.

Why it matters:

Upcoming hearings and agency actions will continue shaping the policy environment around drug pricing, reimbursement, regulatory efficiency, and innovation pathways.

Upcoming Events

GLS Members Only: GBG Monthly Federal Funding Report Call

Don't miss the monthly GBG Report call, held every third Thursday at 12 PM ET. These sessions provide updates on the latest federal funding opportunities and insights to help companies navigate and secure non-dilutive capital. GLS partner G2G has helped raise over \$612M and brings deep expertise in supporting innovation and commercialization. Interested? Contact Stacey Bowlin at Sbowlin@galifesciences.org

Georgia Life Sciences is the leading advocate for the state's life sciences sector. Our team works on behalf of our members to advance policies that support innovation and growth—advocating for federal funding that drives research and enables the approval of new therapies; a fair reimbursement and pricing landscape to ensure patient access to life-saving medicines; continued investment in research and pandemic preparedness; strong intellectual property protections that reward innovation; a business-friendly tax environment that allows companies to thrive and grow; and expanded loan guarantees and grant programs to improve access to capital, including for agricultural and energy biotechnology.

Questions or feedback? Contact us at admin@galifesciences.org.